 |
38 Diseases |  |
10 Trials |
|
10 Trials |  |
381 News |  |
| «1234» |
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Benzalkonium Chloride-Induced Corneal Epithelial Injury in Rabbit Reduced by Rebamipide. (Pubmed Central) - Mar 17, 2022
Findings by FL staining were consistent with those by CR; BAK and latanoprost with BAK groups were positive, and eyes with the most severe area and density of corneal epithelial damage (A2D2) were in the saline/BAK group. The rebamipide ophthalmic solution reduces the severity of corneal epithelial injury caused by BAK, an ophthalmic solution preservative.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER. (Pubmed Central) - Mar 15, 2022
No signal was detected when combining drugs. These results suggest a prophylactic effect of rebamipide on NSAID-induced lower gastrointestinal tract injury.
- ||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal, Adverse events, Adverse drug reaction: The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: an analysis of national pharmacovigilance database in South Korea. (Pubmed Central) - Mar 8, 2022
Rebamipide was less often reported for pulmonary AE. However, healthcare professionals need to be aware of the risk of pulmonary AE in elderly patients.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Engineering a Remedy to Modulate and Optimize Biopharmaceutical Properties of Rebamipide by Synthesizing New Cocrystal: In Silico and Experimental Studies. (Pubmed Central) - Mar 1, 2022
However, healthcare professionals need to be aware of the risk of pulmonary AE in elderly patients. The study ascertains the advantages of cocrystallization, with RCA showing greatest potential and suggests a viable alternative approach for improved formulation of rebamipide.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial initiation date: Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 23, 2022
P1/2, N=100, Not yet recruiting, Sponsor: October 6 University
The study ascertains the advantages of cocrystallization, with RCA showing greatest potential and suggests a viable alternative approach for improved formulation of rebamipide. Initiation date: Jan 2022 --> Apr 2022
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Development and validation of four spectrophotometric methods for assay of rebamipide and its impurity: application to tablet dosage form. (Pubmed Central) - Feb 11, 2022
First derivative, second derivative, derivative ratio, and mean centering methods for quantification of REM and DER. These methods are useful for analysis of REB in pharmaceutical dosage form.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P1/2 trial: Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 20, 2021
P1/2, N=100, Not yet recruiting, Sponsor: October 6 University
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
PK/PD data, Preclinical, Journal: Development of rebamipide-loaded spray-dried microsphere using distilled water and meglumine: physicochemical characterization and pharmacokinetics in rats. (Pubmed Central) - Dec 16, 2021
Furthermore, the drug solubility, dissolution, plasma concentrations, AUC and C values of RSM were significantly higher than those of drug powder and commercial tablet. Thus, this RSN system developed with distilled water and meglumine is recommended as an oral water-soluble rebamipide-loaded pharmaceutical product.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Preparation and Evaluation of a Powdered Rebamipide Mouthwash as In-Hospital Formulation: Considering Dispersion before Use in Patients. (Pubmed Central) - Nov 29, 2021
Although solubility and turbidity seemed to be affected by the type of polymer rather than the particle size, every ground mixture showed high dispersibility. Thus, grinding the RB-Ts with polymers appeared to be the most promising way to obtain stable dispersion as an in-hospital formulation.
- ||| AD-203 / Yuhan Corp, Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, P3 data, Journal, Head-to-Head: Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double- Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study. (Pubmed Central) - Nov 21, 2021
The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
- ||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment open: MCTSRPMS: Post-Marketing Surveillance of Safety and Effectiveness of Mucosta (clinicaltrials.gov) - Oct 19, 2021
P=N/A, N=600, Recruiting, Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
Both formulations showed a similar efficacy in treating erosive gastritis. Not yet recruiting --> Recruiting
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P4 trial, Combination therapy, Monotherapy: Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis (clinicaltrials.gov) - Oct 11, 2021
P4, N=260, Not yet recruiting, Sponsor: Daewoong Pharmaceutical Co. LTD.
- |||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New trial: MCTSRPMS: Post-Marketing Surveillance of Safety and Effectiveness of Mucosta (clinicaltrials.gov) - Sep 17, 2021
P=N/A, N=600, Not yet recruiting, Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: The effect of PPIs Alone, PPIs plus cytoprotective agent, and H2RA plus cytoprotective agent on ulcer healing after endoscopic submucosal dissection: A prospective randomized controlled trial. (Pubmed Central) - Sep 11, 2021
There was no statistical difference in ulcer stage and delayed bleeding after ESD among the groups. These findings showed that PPI + rebamipide had limited benefits after ESD.
- || aspirin / Generic mfg., lansoprazole / Generic mfg.
Retrospective data, Review, Journal: Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis. (Pubmed Central) - Sep 4, 2021
Our study suggested that omeprazole plus rebamipide might be considered the best option to treat aspirin-induced gastrointestinal injury. More multicenter, high quality, large sample size randomized controlled trials will confirm the advantages of these medicines in the treatment of aspirin-induced gastrointestinal injury in the future.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Effect of rebamipide on the acute gouty arthritis in rats induced by monosodium urate crystals (Pubmed Central) - Aug 17, 2021
More multicenter, high quality, large sample size randomized controlled trials will confirm the advantages of these medicines in the treatment of aspirin-induced gastrointestinal injury in the future. Rebamipide has a protective effect on acute gout arthritis rats induced by MUS crystals.
- || dexamethasone / Generic mfg.
Clinical, Journal: Evaluation of Disappearance Time and Palatability of Foams in the Oral Cavities of Healthy Volunteers, and Preparation of Drug-Containing Foam Formulations for Use in the Treatment of Oral Mucositis. (Pubmed Central) - Jul 15, 2021
Drug contents in drug-containing foam formulations which were prepared with 1-4% SM-4 represented 101-112% of the loaded drug contents, and the relative standard deviations of drug contents were <2.2%, which suggests that these formulations had pharmaceutically acceptable properties. This is the first report in regard to foam formulations containing drugs for the prevention and treatment of oral mucositis, and these formulations could be potentially useful for the prevention and treatment of oral mucositis.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers. (Pubmed Central) - Jul 10, 2021
This is the first report in regard to foam formulations containing drugs for the prevention and treatment of oral mucositis, and these formulations could be potentially useful for the prevention and treatment of oral mucositis. The polaprezinc plus PPI treatment showed noninferiority to rebamipide plus PPI treatment in the ulcer healing rate at 4 weeks after ESD.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal, IO biomarker: Hepatoprotective effect of rebamipide against methotrexate-induced hepatic intoxication: role of Nrf2/GSK-3β, NF-κβ-p65/JAK1/STAT3, and PUMA/Bax/Bcl-2 signaling pathways. (Pubmed Central) - Jul 8, 2021
the outcomes of the present study showed REB's ability to protect from hepatic injury induced by MTX, possibly through its antioxidant, anti-inflammatory, and anti-apoptotic properties. These effects could be attributed to REB's ability to modulate, at least in part, the Nrf2/GSK-3β,NF-κβ-p65/JAK1/STAT3, and PUMA/Bax/Bcl-2signaling pathways.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Review, Journal: Diagnostic methods and drug therapies in patients with ischemic colitis. (Pubmed Central) - Jun 24, 2021
These effects could be attributed to REB's ability to modulate, at least in part, the Nrf2/GSK-3β,NF-κβ-p65/JAK1/STAT3, and PUMA/Bax/Bcl-2signaling pathways. Accurate diagnoses and effective treatmentshave helped reduce the mortality rate and improve prognoses for patientsafflicted with IC, and corresponding drug therapies have been constantlyupdated as new research has emerged.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota. (Pubmed Central) - Jun 24, 2021
We found that the transplantation of the small intestinal microbiota of the rebamipide-treated mice ameliorated indomethacin-induced small intestinal damage and the omeprazole-induced exacerbation of the damage. These results suggest that rebamipide exerts a protective effect against NSAID-induced small intestinal damage via the modulation of the small intestinal microbiota, and that its ameliorating effect extends also to the exacerbation of NSAID-induced small intestinal damage by proton pump inhibitors.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Comparison of the intestinal drug permeation and accumulation between normal human intestinal tissues and human intestinal tissues with ulcerative colitis. (Pubmed Central) - Jun 22, 2021
Human intestinal tissues from UC and cancer patients mounted in a mini-Ussing chamber were used to evaluate the permeation of drugs, including FD-4, a very low permeable marker, rebamipide, a low permeable marker, and metoprolol, a high permeable marker...Our finding of the transport characteristics in intestinal tissues of severe UC patients in mini-Ussing chamber system demonstrated that autopsy grade of UC patients didn't drastically change membrane permeability of the tested compounds. Furthermore, it was suggested that morphological changes of intestinal tissues caused by fibrosis led to limited permeation and subsequently increased accumulation with little change of total absorption.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Biopharmaceutical characterization of rebamipide: the role of mucus binding in regional-dependent intestinal permeability. (Pubmed Central) - Jun 22, 2021
Food effect simulations indicated somewhat decreased rebamipide absorption in the fed state, in corroboration with previous reports. Since this anti-ulcer drug is currently examined for additional indications, this work provides important input for future development of rebamipide.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation. (Pubmed Central) - Jun 22, 2021
The additional utilization of Eudragit EPO for SNEDDS preparations of both complexes successfully maintained the high concentrations of rebamipide in the gastric luminal condition. In vivo oral absorption studies clearly indicated that SNEDDS preparations utilizing Reb-counter ion complex successfully improved rebamipide absorption.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Analysis of long-term results of pathogenetic treatment of Helicobacter pylori-associated gastroduodenopathies induced by nonsteroidal anti-inflammatory drugs in patients with osteoarthritis. (Pubmed Central) - Jun 22, 2021
However, these changes were significantly more significant in group I compared to group I. The long-term follow-up showed a declining trend of EDF in all groups. The data obtained indicate the effectiveness of rebamipide in the complex pathogenetic treatment and prevention of Hp-associated GDP induced by NSAIDs in patients with OA.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Preclinical, Journal: Spermine with Sodium Taurocholate Enhances Pulmonary Absorption of Macromolecules in Rats. (Pubmed Central) - Jun 13, 2021
The pulmonary absorption of rebamipide, a low molecular but poorly absorbable drug after oral administration, was significantly improved by the combined use of SPM with STC (SPM-STC formulation), while poly- L-lysine did not show a significant change in rebamipide absorption from the lungs...Our present results clearly indicated that the SMP-STC formulation significantly improved the pulmonary absorption of poorly absorbable small and large molecular drugs without any harmful effects on the lungs. Therefore, the SPM-STC formulation would be a useful one for the pulmonary absorption of drugs, specifically macromolecular ones, which are very difficult to be absorbed after oral administration.
- | valsartan / Generic mfg.
Journal: Mechanistic understanding of salt-induced drug encapsulation in nanosuspension via acid-base neutralization as a nanonization platform technology to enhance dissolution rate of pH-dependent poorly water-soluble drugs. (Pubmed Central) - Jun 3, 2021
Changes in drug crystallinity to the nano-amorphous state were confirmed by powder X-ray diffraction (PXRD). Overall, the salt-induced drug NSP synergistically enhanced the dissolution rate, narrowing a gap between drug dissolution profiles in different pH environments.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Protective effect and mechanism of rebamipide on NSAIDs associated small bowel injury. (Pubmed Central) - May 27, 2021
Overall, the salt-induced drug NSP synergistically enhanced the dissolution rate, narrowing a gap between drug dissolution profiles in different pH environments. Rebamipide effectively alleviated intestinal mucosa injury by probably suppressing the TLR4/NF-κB signaling pathway and the decreasing of ZO-1 and Claudin-1 induced by diclofenac.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P4 trial: CEERS: Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy (clinicaltrials.gov) - May 13, 2021
P4, N=50, Not yet recruiting, Sponsor: Seoul National University Boramae Hospital
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Retrospective data, Journal: Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis. (Pubmed Central) - May 11, 2021
Evidences now available show rebamipide plus PPIs is practical for protecting against ESD-induced ulcers at four weeks but not at eight weeks, especially large ulcers (>20 mm). However, we still need more high-quality RCTs in the future to supplement our conclusions.
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Clinical, Journal: Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. (Pubmed Central) - Apr 23, 2021
The gut microbiota of RA patients receiving PPIs was distinguishable from that of those receiving rebamipide. The enriched virulent function in the gut microbiota of PPI users suggests that inappropriate PPI use may be harmful in RA patients.
- ||||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Trial completion date, Trial primary completion date, Head-to-Head: A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis (clinicaltrials.gov) - Mar 11, 2021
P3, N=392, Completed, Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
The enriched virulent function in the gut microbiota of PPI users suggests that inappropriate PPI use may be harmful in RA patients. Not yet recruiting --> Completed | Trial completion date: Oct 2020 --> Apr 2020 | Trial primary completion date: Oct 2020 --> Apr 2020
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
PK/PD data, Preclinical, Journal: Interspecies Differences on Pharmacokinetics of Rebamipide following Oral Administration to Rats and Dogs. (Pubmed Central) - Mar 10, 2021
Simple allometric approaches showed that the correlation between body weight and Cl /F (R = 0.9287) among rats, dogs, and humans appeared satisfactory. This finding will help not only in understanding the pharmacology of rebamipide but also in establishing a strategy for in vivo evaluation of novel rebamipide formulations.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Pharmaceutical evaluation of matrix tablets prepared using a fused deposition modelling type three-dimensional printer - Effect of geometrical internal microstructural factors on drug release from enteric-polymer tablets containing rebamipide. (Pubmed Central) - Feb 18, 2021
This finding will help not only in understanding the pharmacology of rebamipide but also in establishing a strategy for in vivo evaluation of novel rebamipide formulations. The dissolution of 3-D tablets in the small intestine could be controlled by the tablet geometrical structure.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Solubilization of poorly water-soluble bioactive molecules in neutral aqueous media by complexation with renatured β-1,3-1,6-glucan nanoparticles. (Pubmed Central) - Jan 15, 2021
Herein, renatured β-1,3-1,6-glucan (r-glucan) nanoparticles prepared by neutralization of alkali-denatured β-1,3-1,6-glucan and subsequent centrifugation are used as a host to disperse water-insoluble bioactive molecules (curcumin, all-trans-retinoic acid, and rebamipide) by simple mixing of host and guest solutions...Specifically, curcumin incorporated in γ-CD is released within 5.5 hours, whereas that in the r-glucan complex is released very slowly, with 12% of curcumin in the latter complex retained after 31-day incubation at 37°C. Thus, inclusion protocol simplicity and slow release ability make r-glucan nanoparticles a potential carrier scaffold for various applications.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P3 trial: Comparative Ef?cacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis (clinicaltrials.gov) - Dec 27, 2020
P3, N=100, Active, not recruiting, Sponsor: Cairo University
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Management of Primary Ciliary Dyskinesia (Pubmed Central) - Dec 16, 2020
Hallmark symptom is a chronic airway infection due to mucostasis leading to irreversible lung damage that may progress to respiratory failure...Participating in patient registries facilitates access to clinical and research studies and strengthens networks between centers. In addition, knowledge of genotype-specific course of the disease will offer the opportunity to further improve and individualize patient care.
- ||||||| AD-203 / Yuhan Corp
Trial completion, Head-to-Head: A Study to Evaluate the Efficacy and Safety of AD-203 (clinicaltrials.gov) - Dec 2, 2020
P3, N=475, Completed, Sponsor: Addpharma Inc.
In addition, knowledge of genotype-specific course of the disease will offer the opportunity to further improve and individualize patient care. Not yet recruiting --> Completed
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P3 trial: Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Dec 1, 2020
P3, N=39, Not yet recruiting, Sponsor: Cairo University
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Fungal ball of the maxillary sinus and the risk of persistent sinus dysfunction after simple antrostomy. (Pubmed Central) - Nov 21, 2020
Long term post-operative mucostasis occurred in 17.9% of patients following an adequate maxillary antrostomy for treatment of a fungal ball. Patients with mucostasis had persistent mucosal inflammation and a greater need for further surgery (modified medial maxillectomy).
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Preclinical, Journal: Intra-articular injection of rebamipide prevents articular cartilage degeneration in murine post-traumatic osteoarthritis models. (Pubmed Central) - Nov 19, 2020
Rebamipide down-regulates inflammatory cytokines and catabolic factors and up-regulates anabolic factors in human chondrocytes in vitro. Rebamipide could be an important treatment for prevention of articular cartilage degeneration.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function. (Pubmed Central) - Nov 19, 2020
The results of the in vivo examination revealed that the infiltration of neutrophils under the basement membrane and the disruption of tight junction proteins with BAC injection and rebamipide attenuates the disturbance of tissue construction. These results suggest that rebamipide protects LDECs via an anti-inflammatory effect and preserves the barrier function of those cells.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: A new approach to understanding the pathogenesis and treatment of infectious and inflammatory diseases of the urogenital tract (Pubmed Central) - Nov 18, 2020
Intravesical instillation of rebamipide accelerates the recovery of damaged urothelium and its barrier function, and also influences on bladder hyperactivity. Thus, the first results of using rebamipide in urology are encouraging; however, further researches are required.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. (Pubmed Central) - Oct 28, 2020
Compared to PPI co-treatment, H2RA, misoprostol, rebamipide, and eupatilin co-treatments were associated with occult GI bleeding HRs (95% CIs) of 1.19 (0.79-1.79), 1.58 (0.72-3.46), 1.44 (0.96-2.16), and 3.25 (2.21-4.77), respectively. Our findings suggest that mucoprotective agents, such as rebamipide and misoprostol, as well as acid suppressants, are effective in reducing the risk for GI injury in NSAID users.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Development of novel bilayer gastroretentive tablet based on hydrophobic polymers. (Pubmed Central) - Oct 8, 2020
In conclusion, novel bilayer GR tablets were successfully developed, indicating the potential for widening the application of GR systems to insoluble drugs. The results also suggested numerous advantages of incorporating Kollidon® SR into the production of GR tablets.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway. (Pubmed Central) - Oct 2, 2020
We also found that RBM/CTS NPs suppress macrophage M1 polarization induced by lipopolysaccharide and interferon-γ and inhibit the activation of the NF-κB signaling pathway. Therefore, as a novel therapeutic strategy, intravesical administration of RBM/CTS NPs can effectively avoid drug intolerance and drug wastage, accelerating the postoperative wound repairing of the prostatic urethra by suppressing macrophage M1 phenotype polarization.
- || Mucosta oral (rebamipide oral) / Otsuka, Acucela
Clinical, Review, Journal: Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review. (Pubmed Central) - Sep 21, 2020
The trial design and endpoints used across the studies varied considerably, highlighting the importance of standardization in clinical trials for DED. Recent advances in drug delivery and improved understanding of DED should contribute to new ophthalmic drug approvals.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Rebamipide using in gastroesophageal reflux disease treatment (Pubmed Central) - Sep 20, 2020
The combination of proton pump inhibitors and rebamipide is more effective in relieving of gastroesophageal reflux disease symptoms and reducing recurrence rate of disease. Using rebamipide in the treatment of gastroesophageal reflux disease is justified because this drug has a unique mechanism of action, which eliminating the main stages of pathogenesis of the disease.
- || Mucosta oral (rebamipide oral) / Otsuka, Acucela
Clinical, Review, Journal: Pharmacological and clinical feature of rebamipide: new therapeutic targets (Pubmed Central) - Sep 20, 2020
It is used in endoscopy, ophthalmology, chemotherapy, rheumatology. The aim of this review is to present current information about the pharmacological and clinical feature of rebamipide and to study its therapeutic potential.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New trial: h.Pylori Ttt With Rebamipide (clinicaltrials.gov) - Sep 16, 2020
P, N=60, Not yet recruiting, Sponsor: Assiut University